Bias Correction Methods Explain Much of the Variation Seen in Breast Cancer Risks of BRCA1/2 Mutation Carriers

PURPOSE: Recommendations for treating patients who carry a BRCA1/2 gene are mainly based on cumulative lifetime risks (CLTRs) of breast cancer determined from retrospective cohorts. These risks vary widely (27% to 88%), and it is important to understand why. We analyzed the effects of methods of ris...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :J Clin Oncol
Главные авторы: Vos, Janet R., Hsu, Li, Brohet, Richard M., Mourits, Marian J.E., de Vries, Jakob, Malone, Kathleen E., Oosterwijk, Jan C., de Bock, Geertruida H.
Формат: Artigo
Язык:Inglês
Опубликовано: American Society of Clinical Oncology 2015
Предметы:
Review Articles
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4979233/
https://ncbi.nlm.nih.gov/pubmed/26150446
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2014.59.0463
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы